S. boulardii

PreclinicalSmall molecule

MMuhammad Aamir Latif

S. boulardii is one of 3 small molecule programs targeting Acute Diarrhea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute DiarrheaActive, not recruiting

Acute DiarrheaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Acute Diarrhea

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Approved

—2

Alinia

RRomark Laboratories L.C.

Preclinical

1 3

S. boulardii

MMuhammad Aamir Latif

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Diarrhea1 trial

Zinc Plus Saccharomyces Boulardii Versus Zinc Alone in the Treatment of Acute Diarrhea

Completed·MMuhammad Aamir Latif·N/A·NCT07168304·276 enrolled

Growth1 trial

A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants

Completed·LLingfen Xu, MD·Phase 3·NCT02310425·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S. boulardii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S. boulardii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S. boulardii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Muhammad Aamir Latif company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMuhammad Aamir Latif

S. boulardii

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Diarrhea1 trial

Growth1 trial

References

Drug Info

Quick Facts

Related News